A Prospective Study of Salivary Gland Function in Lymphoma Patients Receiving Head and Neck Irradiation

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 1079-1083

  Rodrigues, Neesha A ^a   Killion, Leah ^a   Hickey, Gail ^a   Silver, Barbara ^a   Martin, Chrystalla ^b   Stevenson, Mary Ann ^b   Mauch, Peter M ^a   Ng, Andrea K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Amifostine; Head and neck; Lymphoma; Quality of Life; Xerostomia

Indexed keywords

ACUTE TOXICITY; AMIFOSTINE; DOSE-VOLUME HISTOGRAMS; DRY MOUTH; EXACT TESTS; HEAD AND NECK; MEAN DOSE; MUCOUS MEMBRANES; POST TREATMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RADIATION THERAPY; SALIVARY DYSFUNCTION; SALIVARY GLANDS; TIME POINTS; XEROSTOMIA;

BODY FLUIDS; DOSIMETRY; PATIENT MONITORING; TOXICITY;

ONCOLOGY;

AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; PREDNISONE; PROCHLORPERAZINE MALEATE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HISTOGRAM; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; IRRADIATION; MALE; MANTLE CELL LYMPHOMA; MINOR SALIVA GLAND; MOUTH DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MUCOSAL DISEASE; NAUSEA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PAROTID GLAND; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; RASH; SALIVA; SALIVARY GLAND; SALIVARY GLAND FUNCTION; SALIVATION; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; SMELLING DISORDER; TASTE DISORDER; TOXICITY; XEROSTOMIA; MIDDLE AGED; MUCOSA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIATION EXPOSURE; RADIATION INJURY; SUBMANDIBULAR GLAND; TIME;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PAROTID GLAND; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; SALIVA; SALIVARY GLANDS; SALIVARY GLANDS, MINOR; SUBMANDIBULAR GLAND; TIME FACTORS; XEROSTOMIA;

EID: 70449702371     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.053     Document Type: Article

References (23)

1. Bucher J.A., Fleming T.J., Fuller L.M., et al. Preliminary observations on the effect of mantle field radiotherapy on salivary flow rates in patients with Hodgkin's disease. J Dent Res 67 (1988) 518-521
2. Keene H.J., Fleming T.J., and Toth B.B. Cariogenic microflora in patients with Hodgkin's disease before and after mantle field radiotherapy. Oral Surg Oral Med Oral Pathol 78 (1994) 577-582
3. Herrin H.K. The oral implications of Hodgkin's disease. Gen Dent 47 (1999) 572-575
4. Li Y., Taylor J.M., Ten Haken R.K., et al. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 67 (2007) 660-669
5. Eisbruch A., Ten Haken R.K., Kim H.M., et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45 (1999) 577-587
6. Roesink J.M., Moerland M.A., Battermann J.J., et al. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys 51 (2001) 938-946
7. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
8. Mossman K.L. Quantitative radiation dose-response relationships for normal tissues in man. II. Response of the salivary glands during radiotherapy. Radiat Res 95 (1983) 392-398
9. Blanco A.I., Chao K.S., El Naqa I., et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1055-1069
10. Bussels B., Maes A., Flamen P., et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 73 (2004) 297-306
11. Maes A., Weltens C., Flamen P., et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 63 (2002) 203-211
12. Anne P.R., Machtay M., Rosenthal D.I., et al. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 67 (2007) 445-452
13. Wasserman T.H., Brizel D.M., Henke M., et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, Phase III trial. Int J Radiat Oncol Biol Phys 63 (2005) 985-990
14. Wasserman T., Mackowiak J.I., Brizel D.M., et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1035-1039
15. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
16. Saarilahti K., Kouri M., Collan J., et al. Intensity modulated radiotherapy for head and neck cancer: Evidence for preserved salivary gland function. Radiother Oncol 74 (2005) 251-258
17. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 (2007) 4873-4879
18. Bhide S., Clark C., Harrington K., et al. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site. Med Dosim 32 (2007) 188-195
19. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 (2006) 981-991
20. Ghielmini M., Van der Bosch S., Bosshard M., et al. Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. Cancer Chemother Pharmacol 47 (2001) 532-536
21. Emmanouilides C., Territo M., Andrey J., et al. A randomized Phase II study of amifostine used as stem cell protectant in non-Hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant. J Hematother Stem Cell Res 10 (2001) 887-893
22. Phillips G.L., Meisenberg B., Reece D.E., et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study. Biol Blood Marrow Transplant 10 (2004) 473-483
23. Gabriel D.A., Shea T.C., Serody J.S., et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 11 (2005) 1022-1030